Advances in computational modelling for personalised medicine after myocardial infarction by Mangion, Kenneth et al.
  
 
 
 
 
Mangion, K., Gao, H., Husmeier, D., Luo, X. and Berry, C. (2017) Advances in 
computational modelling for personalised medicine after myocardial infarction. Heart, 
(doi:10.1136/heartjnl-2017-311449). 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/150638/  
     
 
 
 
 
 
 
Deposited on: 26 October 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
Advances in computational modelling for personalized medicine after 1 
myocardial infarction. 2 
British Society of Cardiovascular Research: Invited Review Article 3 
Authors: Kenneth Mangion MD1,2, Hao Gao PhD3, Dirk Husmeier PhD3, Xiaoyu Luo 4 
PhD3, Colin Berry MBChB, PhD1,2 5 
Institutions: 1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 6 
United Kingdom; 2 West of Scotland Heart and Lung Centre, Golden Jubilee National 7 
Hospital, Clydebank, United Kingdom; 3Department of Mathematics and Statistics, 8 
University of Glasgow, United Kingdom. 9 
Correspondence: Professor Colin Berry, British Heart Foundation Glasgow 10 
Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 11 
126 University Place, University of Glasgow, Glasgow, G12 8TA, Scotland, UK. 12 
Telephone: +44 (0) 141 330 1671 or +44 (0) 141 951 5000. Fax +44 (0) 141 330 6794   13 
Email: colin.berry@glasgow.ac.uk   14 
Key words: myocardial infarction; mathematical modelling; personalised medicine 15 
Word count: 3000 (main text), 237 (abstract).16 
 2 
Abstract  17 
Myocardial infarction (MI) is a leading cause of premature morbidity and mortality 18 
worldwide. Determining which patients will experience heart failure and sudden 19 
cardiac death after an acute MI is notoriously difficult for clinicians. The extent of 20 
heart damage after an acute MI is informed by cardiac imaging, typically using 21 
echocardiography or sometimes, cardiac magnetic resonance. These scans provide 22 
complex datasets that are only partially exploited by clinicians in daily practice, 23 
implying potential for improved risk assessment. 24 
Computational modelling of left ventricular (LV) function can bridge the gap towards 25 
personalised medicine using cardiac imaging in post-MI patients. Several novel 26 
biomechanical parameters have theoretical prognostic value and may be useful to 27 
reflect the biomechanical effects of novel preventive therapy for adverse remodelling 28 
post-MI. These parameters include myocardial contractility (regional and global), 29 
stiffness and stress. Further, the parameters can be delineated spatially to correspond 30 
with infarct pathology and the remote zone. Whilst these parameters hold promise, 31 
there are challenges for translating MI modelling into clinical practice, including 32 
model uncertainty, validation and verification, as well as time-efficient processing.  33 
More research is needed to 1) simplify imaging with CMR in post-MI patients, whilst 34 
preserving diagnostic accuracy and patient tolerance 2) to assess and validate novel 35 
biomechanical parameters against established prognostic biomarkers, such as LV 36 
ejection fraction and infarct size. Accessible software packages with minimal user 37 
interaction are also needed. Translating benefits to patients will be achieved through a 38 
multidisciplinary approach including clinicians, mathematicians, statisticians, and 39 
industry partners. 40 
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Introduction 41 
Ischaemic heart disease is the leading cause of premature disability and death in many 42 
countries worldwide[1]. Despite reductions in age-standardised death rates, the 43 
incidence of heart failure after acute myocardial infarction (MI) remains persistently 44 
high [2]. Left ventricular (LV) dysfunction after MI portends an adverse prognosis[2], 45 
however, LV dimensions change dynamically early post-MI making imaging-guided 46 
risk assessment challenging for clinicians [3] (Figure 1).  47 
The clinician relies on medical imaging to provide global measures of LV systolic 48 
function, such as LV ejection fraction (EF), wall-motion score and myocardial strain. 49 
These indices are indirect measures of LV pump function. In practice, therapeutic 50 
decisions are informed by an evidence base relating to LVEF[2,4]. However, on an 51 
individual patient basis, risk prediction using LVEF is limited as the majority of 52 
patients who die prematurely have normal or mildly reduced LVEF[5]. 53 
Another challenge is the lack of information on infarct size and pathology. Ideally, 54 
LV function should be registered with pathology to provide clinically-relevant 55 
insights into salvaged myocardium and complications, including myocardial 56 
haemorrhage and contained myocardial rupture. Cardiac magnetic resonance (CMR) 57 
imaging provides multi-parametric information in a single scan, and while CMR 58 
uniquely integrates function with pathology, CMR has limited availability daily 59 
practice. 60 
Computational heart modelling has potential to improve risk prediction in individual 61 
patients[6][7]. For example, computed biomechanical parameters of LV function 62 
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(Table 1) may have the potential to provide new knowledge over and above 63 
conventional measures of pump function (e.g. LVEF & myocardial strain)[8–11]. A 64 
number of modelling consortia have emerged since the international Physiome Project 65 
was first proposed at the International Union of Physiological Sciences Council in 66 
Glasgow in 1993. These consortia (Table 2) have potential to push technical advances 67 
through to the clinic. Further integration of medicine with mathematics and statistics 68 
has potential to bring otherwise abstruse biomechanical parameters closer to the clinic, 69 
especially if novel inference techniques from machine learning and multivariate 70 
statistics are employed. 71 
Biomechanical parameters of LV function (i.e. contractility, stiffness, strain) are 72 
theoretically more tightly linked with LV pump performance (and thus prognosis) 73 
than global measures of systolic function such as LVEF. Measurement of these 74 
indices requires model personalization, which presents a barrier translation to the 75 
clinic. Nonetheless, personalized heart-modelling holds exciting potential for a 76 
diverse range of applications, from basic science to therapy development (including to 77 
replace, reduce and refine (3Rs) the need for animals in scientific research), and for 78 
risk stratification of individual patients after acute MI. In this review article, we 79 
provide the reader with a review of recent updates in modelling myocardial infarction, 80 
including the challenges and future promise of computational heart modelling for 81 
personalised medicine. 82 
Imaging myocardial function 83 
The practice guidelines for STEMI issued by the European Society of Cardiology[2] 84 
assign the use of echocardiography with a class 1, level of evidence B indication for 85 
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risk stratification based on assessment of infarct size and resting LV function. CMR 86 
imaging has a class 2a, level of evidence C, i.e., indicated when echocardiography is 87 
not feasible, whereas routine computed tomography is not recommended (class 3, 88 
level of evidence C). The North American guidelines[4] give the assessment of LV 89 
function a class 1, level of evidence C but do not specify the method used. The infarct 90 
territory is inferred by the presence of a wall-motion abnormality[12] and the standard 91 
assessment of LV function post-MI consists of LVEF and wall motion scoring. 92 
Echocardiography has several attributes including portability, high temporal 93 
resolution, shorter scanning time and lower cost. For these reasons, echocardiography 94 
is the standard of care for cardiac imaging in post-MI patients[2]. CMR, however, has 95 
superior accuracy and precision for imaging LV and RV function when compared 96 
with echocardiography[13]. CMR is multi-parametric, thus a single scan provides 97 
information on tissue characteristics[3], infarct pathology[14] and myocardial 98 
viability. CMR does not involve ionising radiation and can be safely repeated. For 99 
these reasons, CMR is the modality of choice for computational modelling of human 100 
hearts [6]. 101 
Clinician’s view of the need for heart modelling 102 
The LVEF is the ratio of blood ejected during systole to the LV volume at the end of 103 
diastole. LVEF is one of the strongest predictors of mortality post-MI to date[2,4,14], 104 
however, it varies with heart rate, blood pressure and inotropic state[15]. Wall motion 105 
scoring is a qualitative, subjective approach for the assessment of LV function. 106 
Assessments of LV function by echocardiography may be imprecise, and potentially 107 
decisions about therapy e.g. mineralocorticoid receptor antagonist, implantable 108 
defibrillator device, may be sub-optimal if based on a single LVEF value. 109 
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Most imaging derived prognostic markers in MI patients have some limitations. 110 
Considering CMR, infarct size may be overestimated in the acute phase due to 111 
oedema[16], and microvascular obstruction and intramyocardial haemorrhage vary 112 
dynamically during the first week following MI[3]. The natural temporal evolution of 113 
LV function and infarct characteristics raises the question of the optimal timing of a 114 
scan post-MI. CMR utility for risk stratification post-MI is identified in updated 115 
guidelines from the European Society of Cardiology[2]. CMR methods continue to 116 
evolve balancing diagnostic utility (e.g. T2*-CMR for myocardial haemorrhage) 117 
against patient-level considerations (scan duration). The optimal timing of a CMR 118 
scan depends on the clinical question. CMR is useful early post-MI (<3 days) for 119 
immediate assessment of risk e.g. LV thrombus, myocardial haemorrhage, and LV 120 
volumes and infarct complications evolve over time[3,16]. Infarct characteristics are 121 
generally stable from 7–10 post-MI permitting longer-term risk stratification. Adverse 122 
remodelling typically becomes established from 3 months. Therefore, multi-123 
parametric CMR helps answer different questions according to the time-point post-124 
MI. 125 
Risk prediction in individual patients is problematic, and improvements are needed to 126 
reliably identify those patients at greatest risk who may benefit from targeted 127 
interventions e.g. defibrillator therapy.  128 
This gap is a target for computational modelling which has potential to define more 129 
informative prognostic biomarkers for stratification of individual patients. Further, 130 
computational modelling has the potential to integrate multiple domains of 131 
information including electrophysiology (i.e. conduction throughout myocardial 132 
tissue), biomechanics, blood flow (4D flow within the LV cavity), myocardial 133 
perfusion, and infarct pathology. This approach is termed ‘multi-scale/physics 134 
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modelling’. Usually, these domains of information are considered in isolation (e.g. 135 
LV function by echocardiography), partially (i.e. cardiac conduction using the surface 136 
electrocardiogram), or not at all (i.e. tissue pathology and 4D-flow, unless CMR is 137 
used). Multi-scale/physics heart modelling holds exciting potential to bring together 138 
key domains of information in one temporally and spatially resolved form. These 139 
concepts are beyond theoretical, and the field of multi-scale/physics modelling is 140 
making important advances towards personalised medicine in the clinic.  141 
Towards clinical translation 142 
Considering the practical challenges, progress is likely to be made with incremental 143 
steps. For example, infarct size and myocardial salvage are not routinely measured 144 
with CMR in clinical practice mainly because of time constraints. Standardised 145 
workflows for CMR imaging post-MI should be developed in parallel with 146 
computational modelling approaches.  In an environment as complex as an infarcted 147 
heart, there are a variety of factors that will influence the success of clinical 148 
treatments. However, reliable computational models based on longitudinal patient-149 
specific CMR imaging can inform the best timing for treatment, monitoring, and 150 
baseline selection. Future advances in personalised medicine are anticipated to lead to 151 
integration of multiscale data (anatomy, pathology, physiology, genomics, etc.) into a 152 
scaled, patient-specific report. 153 
Advances in software and machine learning could make this task more accessible for 154 
clinicians. Beyond this, future advances could lead to registration of these pathologies 155 
with parametric maps of novel biomechanical parameters (i.e. contractility, stiffness).   156 
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Personalised modelling in myocardial infarction  157 
Cardiac modelling and technical considerations 158 
Cardiac biomechanical models are a set of mathematical relationships which describe 159 
myocardial motion and deformation under various loading conditions and constrains, 160 
as governed by the continuum mechanics theory[17]. Cardiac models are usually 161 
implemented using computer languages that produce outputs (deformation, stress, etc.) 162 
from inputs (clinical data etc.) which are run on high performance computers[18].    163 
Cardiac dynamics are complex multi-physics problems that involve myocardial tissue 164 
mechanics, haemodynamics, electrophysiology, biochemistry and their interactions, 165 
spanning from sub-cellular to organ levels[18], as listed in Figure 1. Cardiac models 166 
have been developed over the past decades, ranging from single myocyte models[19], 167 
to two-dimensional approximation[20], three-dimensional models[21], and multi-168 
scale/physics systems[18]. A biomechanical cardiac model encompasses various 169 
components to capture ventricular dynamics[7], including geometrical representation 170 
(numerical mesh), mathematical representation (i.e. finite element methods), 171 
boundary conditions (motion constrain imposed by surrounding tissue and organs, 172 
blood pressure and flow rates), material properties (myocardial passive stiffness and 173 
contractility), and model output analysis  (Figure 2). The development of personalized 174 
heart models is complex and involves multidisciplinary involvement and 175 
collaboration (Figure 3). These include, stage 1: patient enrolment, cardiac imaging 176 
and clinical assessment, by healthcare staff; stage 2: image analysis and personalized 177 
model construction, requiring collaborative work between modellers and cardiologists; 178 
stage 3: mathematical model implementation, calibration, inference, and result 179 
interpretation, mainly performed by mathematical modellers and statisticians.  180 
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Model personalisation 181 
An accurate, fast and reliable heart geometry reconstruction is the first step in clinical 182 
translation. To reconstruct cardiac geometry from in vivo data, endocardial and 183 
epicardial boundaries are delineated from images, i.e. segmentation. At this point, the 184 
endocardial and epicardial borders which are represented by a 3D ‘cloud’ of points 185 
will undergo surface fitting, where a smooth surface is constructed by minimizing the 186 
difference between the points and the fitted surface. The next step is volumetric 187 
meshing, where the LV wall is divided into polyhedrons as small representative solids. 188 
Different methods are being developed for cardiac geometry reconstruction including 189 
user iterative interventions for reconstruction[7] or by warping idealized ventricular 190 
geometry, e.g. an ellipsoid,  into patient data[22]. 191 
Personalized modelling not only depends on anatomically accurate geometry, but also 192 
relies on mathematical formulation and patient-specific material properties as shown 193 
in Figure 2. Knowledge of myocardial passive and active material properties is 194 
essential to accurately predict cardiac function as well as to design and evaluate new 195 
treatment based on those models. Much research has been carried out to estimate 196 
myocardial property from in-vivo data, and to understand heart dysfunction based on 197 
the changes of myocardial mechanical properties. 198 
Mathematical descriptions of passive myocardium[23] have progressed from linear 199 
material to nonlinear material laws by considering myocyte organization and its 200 
associated collagen networks[6]. However, non-invasively estimating material 201 
parameters remains a great challenge. Inverse approaches for determining myocardial 202 
material parameters have attracted much interest, in which one can estimate the 203 
unknown parameters by minimizing the difference between in-vivo measurements 204 
(displacement, strain, pressure-volume curve) and the modelling results with respect 205 
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to those unknown parameters[20,24–27](Figure 4). However, due to the excessively 206 
large number of potential parameter combinations, and their non-linear influence on 207 
predictions, the practical realisation of this task is not trivial, and depends on the 208 
execution of computer-intensive optimisation algorithms. Recently, more advanced 209 
techniques from computational statistics and machine learning, such as Bayesian 210 
optimisation and statistical emulation, are being used[28]. 211 
Predicting myocardial systolic stress also requires further parameterisation of the 212 
active contraction model, which usually complements a myocardial passive response 213 
model[7]. Most of myocardial active models are based on ‘the sliding theory’ at 214 
cellular level and up-scaled to tissue level (Table 1). At cellular level, the active 215 
tension can be described as a function of intracellular calcium, sarcomere length, and 216 
contraction velocity. At tissue level, active tension is a function of myocyte 217 
organization and individual myocyte contractility. Due to the large set of unknown 218 
parameters in the active contraction model, parameterisation is usually carried out at 219 
tissue level, by scaling cellular active tension so that myocardial motion in systole 220 
matches in-vivo measurements[21] (Figure 4). 221 
Left ventricular pressure is a loading condition, and when LV pressure is not available, 222 
computational estimates of cardiac dynamics become less certain. The ratio between 223 
early mitral inflow velocity and mitral annular early diastolic velocity has been used 224 
to estimate the ventricular filling pressure, but this can be unreliable in certain 225 
situations[29]. Systolic ventricular pressure may be inferred from non-invasive cuff-226 
measured blood pressure or by measuring flow in large arteries through coupling 227 
circulation models[30]. Non-invasively measuring the absolute blood pressure is 228 
challenging, though pressure gradients can be estimated from flow measurements. 229 
The underlining myocyte architecture and collagen network also play an essential role 230 
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in determining pump function. Diffusion tensor MRI (DT-MRI) reveals fibre 231 
organization[31]. However, it is still a work-in-progress due to challenges presented 232 
by cardio-respiratory motion. Therefore, most cardiac models used rule-based 233 
approaches to describe their organizations[9,21,32,33], which inevitably contribute to 234 
model uncertainty for predictive modelling. Our recent modelling study demonstrated 235 
that myocyte architecture is an important factor for estimating myocardial 236 
contractility[8].  237 
Biomechanical findings from personalized heart models  238 
Clinically, increased passive myocardial stiffness is a major cause of impaired LV 239 
pump function due to inadequate diastolic filling and subsequent increased end-240 
diastolic pressure[34]. Image-based cardiac models[25,27,33,35–38] have been 241 
developed for estimating myocardial passive stiffness in both healthy subjects and 242 
patients with heart failure. These models were constructed utilising CMR imaging 243 
(cine, 3D tagging and flow imaging)[27,33] or a combination of CMR imaging (cine, 244 
tagging) and invasive LV end-diastolic pressure measurements[25]. Nevertheless, 245 
although different myocardial constitutive laws are used in the above studies either 246 
with invasively or non-invasively measured or population-based ventricular pressure, 247 
the findings from computational cardiac models seem consistent. The myocardium 248 
from diseased hearts is stiffer compared to healthy hearts. 249 
Post-MI passive stiffness is highest at 1 week followed by improvements with 250 
remodelling by 12 weeks[39]. From animal and human studies, Guccione’s group[9–251 
11] has reported that the infarcted region not only has a higher passive stiffness and 252 
higher wall stress when compared to remote myocardium, but the myocardial 253 
contractility in the border zone is reduced as well, correlating with the area-at-risk. 254 
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They suggested that adverse remodelling post-MI could be due to an altered 255 
myocardial stress pattern. Porcine biomechanical heart models[40] have disclosed that 256 
remote myocardial contractility increases at 10 days and 38 days post-MI. Several 257 
computational studies have reported that maximal active tension is much higher in 258 
patients with heart failure when compared to normal subjects[7,33], and in patients 259 
with MI[21], suggesting an increased dependency on myocardial contractile reserve. 260 
However, computationally estimated myocardial passive stiffness and contractility 261 
vary considerably between healthy and diseased hearts (Table 3.) The reasons for this 262 
variability are unclear but may be related to inter-individual variations, sample size, 263 
or technical factors. 264 
Ventricular wall stress and its inhomogeneous distribution could also lead to adverse 265 
remodelling, including myocardial hypertrophy, and heart failure[41]. Figure 5 shows 266 
the LV systolic stress patterns in a healthy control and a patient post-MI. Clearly, 267 
there is a more homogenous distribution of LV stress in health, and restoring 268 
ventricular stress to a normal stress distribution could be a potential therapeutic 269 
target[42](Table 3). Further work is needed to investigate the effect of sex, age and 270 
anthropometry on myofibre stress.  271 
Recently, we utilised an “extreme case-control” study design, with cardiac modelling 272 
undertaken in 27 healthy controls and 11 post-MI patients[8]. By combining 273 
computational modelling with machine-learning approaches, we reported that 274 
myofibre active tension is much higher in MI patients compared to healthy volunteers, 275 
and myocardial contractility correlated negatively with the observed recovery in LV 276 
pump function at six months post-MI. By contrast, LVEF was not associated with LV 277 
outcomes at 6 months. We observed moderately strong predictive associations for the 278 
biomechanical parameters despite the sample size being limited. Future prospective 279 
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studies should evaluate whether novel biomechanical parameters (Table 1) have 280 
superior prognostic value in post-MI patients as compared to standard indices such as 281 
LVEF. 282 
Challenges in personalised modelling 283 
Model uncertainty and metrology 284 
Uncertainty quantification in heart models is essential to support the use of these 285 
techniques as tools to aid clinical decision-making[43]. Specific topics for uncertainty 286 
evaluation include (1)in-vivo imaging acquisition (noise, incomplete heart structure 287 
representation); (2)image segmentation; (3)model construction; (4)model 288 
simplification (heterogeneity); (5)material laws assumptions (linear, nonlinear) and 289 
boundary conditions; (6)model abstraction from subcellular to organ levels; (7)multi-290 
physics domains e.g. electrophysiology[44,45]. These uncertainties may be either 291 
directly measured, i.e. imaging noise, or indirectly inferred such as material laws.  292 
Increasingly, computer-intensive statistical inference is being used to quantify 293 
uncertainty in parameter estimation, model selection and model prediction, utilizing 294 
methods such as Bayesian filtering[46], Markov chain Monte Carlo[47] and Gaussian 295 
process emulators[28]. Uncertainty quantification in cardiac models should be a high 296 
priority to ensure successful future clinical translation[43].  297 
Validation and verification 298 
Some validation has been achieved to date through comparisons with experimental 299 
benchmark data[48], computational models[49], and clinical images. However, 300 
substantial challenges exist, as directly validating stress and myocardial contractility 301 
in vivo is next to impossible. Novel non-invasive techniques such as magnetic 302 
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resonance elastography[50] and DTI[31] hold promise for assessing the mechanical 303 
properties of tissue in-vivo. Recently, there has been growing interest in the 304 
development of methodologies and frameworks for verification, validation and 305 
uncertainty quantification (VVUQ) in order to improve model credibility[44].  306 
Clinical Perspective and Future Directions 307 
Computational modelling is currently operative mainly within the domain of cardiac 308 
science. Recent advances support a forward-looking view, and personalized 309 
computational heart modelling has realistic potential to provide clinicians with new 310 
predictive tools, that currently are not available in daily practice[7].  311 
Bringing models into the clinic for patient benefits presents an exciting challenge 312 
(please see Online Supplement). In the future, modelling applications for risk 313 
stratification should ideally exploit echocardiography (since this is the standard of 314 
care) or CMR. Machine learning and statistical emulation techniques will be 315 
necessary to enable software applications for near real-time use in the clinic.  316 
Further work should establish a minimum-dataset of what imaging to acquire in post-317 
MI patients, the timing of the imaging scans, validate novel biomechanical parameters 318 
against more established prognostic markers, such as LVEF, e.g. in multicentre 319 
studies. Technical innovations should lead to software packages that require minimal 320 
user interaction. Our view is that adoption in the clinic is most likely through 321 
incremental steps with adoption of software tools (patches, programmes, etc.) that 322 
build on existing clinical workflows. To this end, clinicians, mathematicians, 323 
statisticians, and industry partners must work collaboratively. 324 
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Conclusion 325 
Imaging-derived heart models have a number of potentially useful applications. Novel 326 
biomechanical parameters including myocardial contractility, stiffness, stress, and 327 
their distribution, have potential as novel surrogates in therapeutic studies and for risk 328 
stratification of individual patients. Multi-scale/physics models that integrate multiple 329 
forms of information hold promise for personalised medicine.  330 
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Figure Legends  523 
Figure 1. Similar presentations yet divergent outcomes. Two male patients presented 524 
with anterior ST elevation MI and had primary angioplasty to their proximal left 525 
anterior descending artery. They were enrolled in the British Heart Foundation MR-526 
MI study (ClinicalTrials.gov identifier NCT02072850). Patient A was a 56 year old 527 
male, who had a symptom to balloon time of 209 minutes. MRI on day 2 revealed a 528 
LV ejection fraction of 47.4%, and indexed LV end-diastolic volume of 85.6 ml/m2. 529 
Infarct size (A.2, yellow arrows) at baseline was 34.9% LV mass. Microvascular 530 
obstruction (A.2, red thin arrows) was 2.89% LV mass. At 6 months follow-up (A.3), 531 
his LV ejection fraction improved to 56.1%, with no significant change in indexed LV 532 
end-diastolic volume (88.3ml/m2). 533 
Patient B was a 58 year old male, who had a symptom to balloon time of 132 minutes. 534 
MRI on day 2 revealed a LV ejection fraction of 46.4%, and indexed LV end-diastolic 535 
volume of 98.2 ml/m2. Infarct size at baseline was 32.4% LV mass. Microvascular 536 
obstruction (A.2, red thin arrow) was 0.08% LV mass.  At 6 months follow-up (A.3), 537 
his LV ejection fraction deteriorated to 36.9%, with adverse remodelling (indexed LV 538 
end-diastolic volume 126.4 ml/m2). He proceeded to have an internal cardiac 539 
defibrillator implanted for primary prevention.  540 
Figure 2. The distinct components of a mathematical cardiac model. 541 
Figure 3. Stage 1 involves patient enrolment and diagnosis, and cardiac imaging such 542 
as magnetic resonance imaging (MRI). The MRI images are all co-registered at the 543 
same position and depict a short axial mid-left ventricular position. (a.1): cine image, 544 
(a.2): T2-weighted image for oedema (red arrow) (a.3, a.4): late gadolinium enhanced 545 
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image for myocardial infarction (red arrow), (a.5) circumferential strain map. Stage 2 546 
involves image analysis and model construction. (b.1, b.2) ventricular wall boundary 547 
segmentation, (b.3) pathological region identification, (b.4) 3-dimensional LV 548 
geometry, (b.5) AHA-17 segmental mapping. Stage 3 depicts mathematical modelling. 549 
(c.1) mesh representation, (c.2, c.3) cardiac dynamics simulation at end-diastole and 550 
end-systole, (c.4) systolic stress distribution, (c.5) ventricular flow in diastolic filling.  551 
Figure 4. Schematic illustration of inversely estimating unknown parameters in 552 
modelling myocardial passive stiffness and active contraction. 553 
Figure 5. Examples of biomechanical models of left ventricular function for a healthy 554 
left ventricle (a, b), and a MI heart (c, d) from the authors’ group, adapted from[8]. (a) 555 
is the LV geometry from a healthy volunteer, and (b) shows the systolic stress along 556 
myocytes, in general, systolic stress is homogeneous throughout the whole ventricular 557 
wall. (c) is the LV geometry from a MI patient, red to blue colour suggests the MI 558 
extent from 1 to 0, which means blue (0) is functional myocardium, red (1) is the 559 
infarct region; (d) is the systolic stress along myocyte in the MI model, high stress 560 
regions can be found in the MI region, and less homogeneous compared to the healthy 561 
heart model in (b).  562 
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Table 1. Examples of biomechanical parameters of left ventricular pump function 563 
derived from mathematical modelling.  564 
Myocardial biomechanics 
parameter 
Definition 
1. Passive stiffness   The relationship between myocardial stress and myocardial strain. 
Stiffness represents the hyper-elastic properties of myocardium, and is a 
passive component of diastolic function. 
2. Required contractility   active tension generated by the sarcomere, the basic contractile unit in 
myocytes, at its resting length, it is the required minimum contractile 
function to meet the body’s blood demand. It is different from the 
maximum contractile function, the difference between the maximum 
contractile function and the required contractility is the contractile reserve. 
3. Systolic stress pattern   The sum of active stress + passive stress in systole, it can be normalized 
by systolic blood pressure, denoted as normalized stress. Stress is the force 
per unit area at any point, active stress means the force is generated by 
myocyte contractile units triggered by intracellular calcium, whereas 
passive stress is the force resulted from resistance to myocardial 
deformation, which does not involve energy consumption, for example, 
when collagen is stretched, there is a force inside collagen to 
counterbalance the external stretching force.   
4. Systolic myofilament 
kinetics 
 The ratio between systolic active stress and the required contractility. 
Systolic active stress is the actual myocardial active force, which is a 
function of contractility, myocardial deformation, etc. Systolic myofilament 
kinetics reflects the quantity of binding sites formed between myosin and 
actin in systole.  
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Table 2. Research consortia on mathematical modelling of the cardiovascular system. 565 
Cardiac modelling 
consortium  
Organization and 
funding body 
Aims Related heart research Output and application 
examples 
The Physiome Project 
(www.physiomeproject.org) 
Started from the 
International Union of 
Physiological Sciences 
council in 1993 
 
To develop a multi-scale modelling 
framework for understanding 
physiological function, allowing models 
to be combined and linked in a 
hierarchical fashion. 
Electromechanical models of the 
heart, myocardial ion channels, 
myofilament mechanics and signal 
transduction pathways, tissue 
mechanics, coronary blood flow, 
etc. 
1. Standardized mark-up 
languages for encoding 
models 
2. Model repositories for 
sharing and collaborating  
3. the physiome modelling 
framework  
 
The EUheart project 
(www.euheart.eu) 
Funded by FP7 with 16 
industrial, clinical and 
academic partners 
To develop individualized, computer-
based human heart models for improving 
the diagnosis, therapy planning and 
treatment of cardiovascular disease 
Focusing on model personalization, 
arrhythmias, coronary disease, heart 
failure, etc. 
Cardiac resynchronisation 
therapy  
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The Sim-e-Child project 
(http://www.sim-e-
child.org) 
Funded by FP7, as a 
follow-up to Health-e-
Child project 
To integrate innovative disease models 
and complex data with knowledge 
discovery applications to support clinical 
decisions in paediatrics diseases  
Developments and application 
cardiac models for congenital heart 
diseases using grid-enabled platform 
for largescale simulations 
Personalized virtual child 
heart modelling 
framework  
CARDIOPROOF 
(www.cardioproof.eu/) 
Funded by FP7, a 
proof-of-concept of 
model-based 
cardiovascular 
predictions from VPH 
To consolidate and check the applicability 
and effectiveness of existed predictive 
modelling tools, and validate in clinical 
trials 
Focusing on patients with aortic 
valve disease and aortic coarctation 
Integration of software 
technologies into clinical 
decision making and 
treatment planning 
systems, for example, the 
virtual stenting solution  
 
The virtual rat physiology 
(www.vph-institute.org) 
An international non-
profit organization to 
ensure the realization 
of the virtual 
physiological human 
project 
To develop new methods and 
technologies to make possible the 
investigation of the human body as a 
whole by integrating knowledge from 
different fields 
Activities and facilities to promote 
collaborative research of the human 
body as a single complex system. 
Development of standards 
for models and data, 
establish model and data 
repositories, and 
associated toolkits  
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The EPSRC centre for 
multiscale soft tissue 
mechanics  
(www.softmech.org) 
Funded by EPSRC UK 
with School of 
Mathematics and 
Statistics, University of 
Glasgow 
To develop a multi-scale soft tissue 
models for heart diseases by integrating 
mathematicians, clinicians, 
experimentalists, and modellers to 
elucidate the chain of events from 
mechanical factors at a subcellular level 
to cell and tissue response  
 
Novel multiscale mathematical 
models and computer-intensive 
statistical inference techniques 
applicable to heart diseases, in 
particular myocardial infarction 
Personalized models in 
patients following acute 
ST-segment elevation 
myocardial infarction, 
three potential 
biomechanical parameters 
were identified using 
machine learning 
approaches  
 
The Virtual Physiological 
Rat Project 
(http://www.virtualrat.org) 
Funded by NIH USA 
focusing on the system 
biology of 
cardiovascular disease  
To understand how disease phenotypes 
apparent at the whole-organism scale 
emerge from molecular, cellular, tissue, 
organ, and organ-system interactions 
Developing a 
theoretical/computational 
understanding of cardiovascular 
system dynamics and the aetiology 
of hypertension 
Developing multi-scale 
models to construct and 
assess competing 
hypothesis across different 
species  
Note: all websites were accessed on 23rd April 2017. This is not an exhaustive list of groups on computational cardiac modelling, other research 566 
groups include MD-Paedigree (http://www.md-paedigree.eu/), LifeV (http://www.lifev.org), Continuity (http://www.continuity.ucsd.edu), 567 
CMISS (http://www.cmiss.org), Chaste (http://www.cs.ox.ac.uk/chaste/), GlasgowHeart (www.glasgowheart.org), CHeart (http://cheart.co.uk). 568 
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Table 3. Summary of estimated myocardial contractility from computational models derived from in vivo cardiac imaging. 569 
Studies Imaging modality Number of subjects Ventricular pressure Myocardial contractility  
Genet et al, 2014 [32] Tagged MRI 5 HVs Assumed pressure 143 kPa 
Genet et al, 2015 [36] 3D cine, 3D tagged, 2D 
LGE MRI 
1 MI patient Assumed end-diastolic and cuff-
measured end-systolic pressure 
146.9 kPa 
Wenk, et al, 2012 [11] Tagged and LGE MRI 1 MI patient Direct, invasive measurement  109.5 kPa 
Wang et al, 2013 [37] Cine MRI 6 HVs,  
5 hypertrophic HF 
9 non-ischemic HF 
Assumed pressure 88 kPa (HV) 
160 kPa (hypertrophic) 
124 kPa (NI- HF) 
Gao et al, 2014 [21] Cine MRI 1 HV 
1 MI patient 
Assumed end-diastolic and cuff-
measured end-systolic pressure 
168.6 kPa (HV) 
309.1 kPa (MI) 
Asner et al, 2015 [33] Cine, 3D tagged, and 4D 
flow MRI 
1 HV 
2 patients with DCM 
Non-invasively estimated pressure 139 kPa (HV) 
168 kPa (patients) 
Land et al, 2017 [38] CT imaging 3 patients with preserved 
heart function 
Assumed pressure 120 kPa 
DCM – dilated cardiomyopathy, HF: heart failure, HV: healthy volunteer, LGE: late gadolinium enhancement, kPa: kilo Pascal. 570 
